Deoxyspergualin: mechanism of action and pharmacokinetics

Transplant Proc. 1996 Apr;28(2):873-5.

Authors

E L Ramos¹, S G Nadler, D M Grasela, S L Kelley

Affiliation

¹ Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, Connecticut 06492-7660, USA.

PMID: 8623442

No abstract available

Publication types

Review

MeSH terms

Animals
Antibody Formation / drug effects
Arthritis, Rheumatoid / drug therapy
Cell Nucleus / physiology
Guanidines / pharmacokinetics*
Guanidines / pharmacology*
Guanidines / therapeutic use
Humans
Immunosuppressive Agents / pharmacokinetics*
Immunosuppressive Agents / pharmacology*
Immunosuppressive Agents / therapeutic use
Kidney Transplantation / immunology
Models, Biological
Multiple Sclerosis / drug therapy
NF-kappa B / antagonists & inhibitors
NF-kappa B / metabolism
Neoplasms / drug therapy
T-Lymphocytes / drug effects
T-Lymphocytes / immunology

Substances

Guanidines
Immunosuppressive Agents
NF-kappa B
gusperimus